SciELO - Scientific Electronic Library Online

vol.45 issue6Evaluation of an in-house specific immunoglobulin G (IgG) avidity ELISA for distinguishing recent primary from long-term human cytomegalovirus (HCMV) infectionCerebral mass lesion due to cytomegalovirus in a patient with AIDS: case report and literature review author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista do Instituto de Medicina Tropical de São Paulo

On-line version ISSN 1678-9946


PINTO, Ana Yecê das Neves; AZEVEDO, Carolina Heitmann; SILVA, Janaína Bezerra da  and  SOUZA, José Maria de. Assessment of chloroquine single dose treatment of malaria due to Plasmodium vivax in Brazilian Amazon. Rev. Inst. Med. trop. S. Paulo [online]. 2003, vol.45, n.6, pp.327-331. ISSN 1678-9946.

Malaria regions of the Amazon basin have been characterized by difficult access and non-compliance of the patients to treatment. In an attempt to assess the schizonticide efficacy of chloroquine in a single dose of 600 mg, the authors realized a double-blind, placebo-controlled trial in 132 outpatients with vivax malaria. Patients were distributed into two groups: group CPLA, given chloroquine 600 mg (single dose) on the first day of treatment, and two doses of placebo on second and third days. Group CHLO, given chloroquine 600 mg on first day and 450 mg on second and third day. Geometric means of the parasite density during the follow-up was similar in both groups. No differences were observed in the parasitological cure between the two groups (p = 0.442). There was clinical and parasitological efficacy in treatment of patients given a single-dose of chloroquine. This suggests that its restricted use could be indicated in remote areas of Brazilian Amazon Region, nevertheless the inadequate response of three patients indicates the need for further studies.

Keywords : Vivax Malaria; Chloroquine; Treatment.

        · abstract in Portuguese     · text in English     · English ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License